Literature DB >> 32271418

Hsa_circ_0007534 knockdown represses the development of colorectal cancer cells through regulating miR-613/SLC25A22 axis.

D-Y Ding1, D Wang, Z-B Shu.   

Abstract

OBJECTIVE: Colorectal cancer (CRC) is a common tumor around the world. Circular RNAs (circRNAs) have been reported to be related to the development of CRC. However, the detailed mechanism is complicated. This study aimed to reveal the functional mechanism of circ_0007534 in CRC. PATIENTS AND METHODS: Quantitative real time polymerase chain reation (qRT-PCR) and Western blot assay were performed to analyze gene expression. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and colony formation assay were carried out to determine cell proliferation ability. Furthermore, cell migratory and invasive abilities were assessed by transwell assay. Glycolytic metabolism was examined via the measurements of extracellular acidification rate (ECAR), glucose consumption, and lactate production. Also, the interaction between circ_0007534 or solute carrier family 25 member 22 (SLC25A22) and miR-613 was predicted and confirmed by starBase v2.0 and the Dual-Luciferase reporter assay, respectively. Mouse xenograft was performed to investigate the effect of circ_0007534 on tumor growth in vivo.
RESULTS: Circ_0007534 and SLC25A22 levels were upregulated, and miR-613 level was downregulated in CRC tissues/cells. Circ_0007534 knockdown repressed CRC cell proliferation, colony formation, migration, invasion, and glycolysis. Interestingly, Circ_0007534 targeted miR-613, and miR-613 targeted SLC25A22. Circ_0007534 exerted its function by repressing miR-613 expression, and miR-613 exerted its function via inhibiting SLC25A22 expression. Also, Circ_0007534 repressed miR-613 expression to upregulate SLC25A22 level. Circ_0007534 depletion repressed tumor growth in vivo.
CONCLUSIONS: We demonstrated that circ_0007534 knockdown suppressed the growth of CRC cells by regulating miR-613/SLC25A22 axis, providing potential target for the treatment of CRC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32271418     DOI: 10.26355/eurrev_202003_20665

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

Review 1.  Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star.

Authors:  Qun Chen; Jiajia Li; Peng Shen; Hao Yuan; Jie Yin; Wanli Ge; Wujun Wang; Guangbin Chen; Taoyue Yang; Bin Xiao; Yi Miao; Zipeng Lu; Pengfei Wu; Kuirong Jiang
Journal:  Cell Biosci       Date:  2022-06-21       Impact factor: 9.584

2.  circ_0136666 Facilitates the Progression of Colorectal Cancer via miR-383/CREB1 Axis.

Authors:  Yuhui Li; Hongliang Zang; Xue Zhang; Guomin Huang
Journal:  Cancer Manag Res       Date:  2020-08-04       Impact factor: 3.989

3.  The Use of circRNAs as Biomarkers of Cancer.

Authors:  Carla Solé; Gartze Mentxaka; Charles H Lawrie
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Comprehensive landscape and future perspectives of circular RNAs in colorectal cancer.

Authors:  Fei Long; Zhi Lin; Liang Li; Min Ma; Zhixing Lu; Liang Jing; Xiaorong Li; Changwei Lin
Journal:  Mol Cancer       Date:  2021-02-03       Impact factor: 27.401

5.  Osthole exhibits an antitumor effect in retinoblastoma through inhibiting the PI3K/AKT/mTOR pathway via regulating the hsa_circ_0007534/miR-214-3p axis.

Authors:  Xiufang Lv; Haojiang Yang; Hui Zhong; Li He; Li Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

6.  circRNA Expression Pattern and circRNA-miRNA-mRNA Network in HCs, HSCs, and KCs of Murine Liver After Echinococcus multilocularis Infection.

Authors:  Tingli Liu; Liqun Wang; Hong Li; Yanping Li; Guoliang Chen; Guiting Pu; Xiaola Guo; Yadong Zheng; Xue Bai; Xuenong Luo
Journal:  Front Vet Sci       Date:  2022-03-24

Review 7.  Circular RNAs in gastrointestinal cancer: Current knowledge, biomarkers and targeted therapy (Review).

Authors:  Xiaorui Zhao; Yue Wang; Qiongfang Yu; Pei Yu; Qiaoyu Zheng; Xue Yang; Dian Gao
Journal:  Int J Mol Med       Date:  2020-09-16       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.